ID: h-7000ac15c1
Hypothesis
Therapeutic Window Exists Because Amplified Signals (Not Baseline) Drive Pathogenesis (H3)
G2019S basal RAB10 phosphorylation elevation may be secondary; true pathogenic driver is amplified stress-response signaling.
EvidencePending (0%)📖 8 cit🗣 1 debates✓ 8 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
G2019S basal RAB10 phosphorylation elevation may be secondary; true pathogenic driver is amplified stress-response signaling. Partial LRRK2 inhibition sufficient to normalize stress-induced spikes while preserving necessary baseline functions. LRRK2 knockout mice viability supports non-essential baseline hypothesis. Age-dependent neurodegeneration in knock-in mice suggests stress-dependent pathology rather than chronic baseline elevation.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["LRRK2 Mutation<br/>Gain of Function Kinase"]
B["Amplified Signaling<br/>Not Baseline Activity"]
C["Pathological Signaling<br/>Threshold Exceeded"]
D["Neuronal Vulnerability<br/>vs Resilience"]
E["Lysosomal Dysfunction<br/>Autophagy Impairment"]
F["Therapeutic Window<br/>Exists"]
G["Signal Reduction<br/>as Intervention Target"]
A --> B
B --> C
C --> D
D --> E
B --> F
F --> G
G --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix8 supports2 contradicts
Supports
Genetic overlap between ALS and other neurodegenerative or neuromuscular disorders.
Supports
Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis.
Supports
The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity.
Supports
Autophagy and mitophagy at the synapse and beyond: implications for learning, memory and neurological disorders.
Contradicts
Lung foamy macrophage findings suggest safety may require complete inhibition
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — LRRK2
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for LRRK2 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for LRRK2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 1.1%
Volatility
Medium
0.0361
Events (7d)
3
Price History
▼18.4%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF partial LRRK2 kinase inhibition is sufficient to normalize amplified stress-induced signaling while preserving baseline functions, THEN low-dose MLi-2 treatment (10 mg/kg/day, achieving ~50% kinase | Low-dose MLi-2 (partial inhibition) and LRRK2 KO will produce statistically equivalent neuroprotection (p>0.05 between these groups) with normalized stress-indu | — no observation — | pending | 0.55 |
| IF G2019S LRRK2 pathogenicity is driven by amplified stress-response signaling (not baseline RAB10 phosphorylation elevation), THEN acute neuroinflammatory stress challenge using systemic LPS (5 mg/kg | G2019S KI mice will show significantly amplified RAB10 phosphorylation responses (p<0.01) and exacerbated neurodegeneration following repeated LPS stress, where | — no observation — | pending | 0.65 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF G2019S LRRK2 pathogenicity is driven by amplified stress-response signaling (not baseline RAB10 phosphorylation elevation), THEN acute neuroinflammatory stress challenge using systemic LPS (5 mg/kg, biweekly for 3 months) will produce disproportionately larger RAB10 phosphorylation spikes and acc
Predicted outcome: G2019S KI mice will show significantly amplified RAB10 phosphorylation responses (p<0.01) and exacerbated neurodegeneration following repeated LPS str
Falsification: If wild-type and G2019S KI mice show equivalent RAB10 phosphorylation responses and neuronal loss after identical stress challenges, the stress-amplification hypothesis is disproven. Alternatively, if
pendingconf 55%
IF partial LRRK2 kinase inhibition is sufficient to normalize amplified stress-induced signaling while preserving baseline functions, THEN low-dose MLi-2 treatment (10 mg/kg/day, achieving ~50% kinase occupancy) will achieve equivalent neuroprotection as complete LRRK2 knockout in G2019S KI mice sub
Predicted outcome: Low-dose MLi-2 (partial inhibition) and LRRK2 KO will produce statistically equivalent neuroprotection (p>0.05 between these groups) with normalized s
Falsification: If complete LRRK2 knockout provides significantly greater neuroprotection (p<0.05) than partial MLi-2 inhibition, demonstrating a dose-response relationship where more inhibition equals more protectio
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.